Patterns Of Hedgehog Inhibitor (HHI) Treatment Interruptions and Reinitiations Among Patients with Basal Cell Carcinoma (BCC) in Real-World Clinical Practice

Main Article Content

Jessica Jalbert
Regeneron Pharmaceuticals, Inc., Tarrytown, NY

Chieh-I Chen
Regeneron Pharmaceuticals, Inc., Tarrytown, NY

Ning Wu
Regeneron Pharmaceuticals, Inc., Tarrytown, NY

Matthew Fury
Regeneron Pharmaceuticals, Inc., Tarrytown, NY

Wenzhen Ge
Regeneron Pharmaceuticals, Inc., Tarrytown, NY

Emily Ruiz
Brigham and Women?s Hospital, Boston, MA

Keywords

Skin Cancer, Basal cell Carcinoma, Hedgehog Inhibitor, Real-World

Abstract

Abstract not available.

References

1. Migden MR et al. Cancer Treat Rev. 2018;64:1–10.

2. Lear JT et al. Br J Cancer. 2014;111:1476–1481.

3. Kudchadkar R et al. Semin Oncol. 2012;39:139–144.

4. American Cancer Society. Treating basal cell carcinoma; 2019. Available at: https://www.cancer.org/cancer/basal-and-squamous-cell-skin-cancer/treating/basal-cell-carcinoma.html. [Accessed July 24, 2020].

5. Trakatelli M et al. Eur J Dermatol. 2014;24:312–329.

6. National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology: basal cell skin cancer version 1.2020; 2019. Available at: https://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdf. [Accessed June 2, 2020].

7. Cancer Council Australia/Australian Cancer Network. Basal cell carcinoma, squamous cell carcinoma (and related lesions) – a guide to clinical management in Australia; 2008; 2008. Available at: https://www.cancer.org.au/content/pdf/HealthProfessionals/ClinicalGuidelines/Basal_cell_carcinoma_Squamous_cell_carcinoma_Guide_Nov_2008-Final_with_Corrigendums.pdf. [Accessed July 24, 2020].

8. Goldenberg G et al. J Am Acad Dermatol. 2016;75:957–966.

9. Sekulic A et al. J Am Acad Dermatol. 2015;72:1021–1026 e1028.

10. Basset-Seguin N et al. Eur J Cancer. 2017;86:334–348.

Article Sidebar

Poster PDF
Published
Oct 27, 2020
DOI https://doi.org/10.25251/skin.4.supp.123

Article Details

How to Cite
Jalbert, J., Chen, C.-I., Wu, N., Fury, M., Ge, W., & Ruiz, E. (2020). Patterns Of Hedgehog Inhibitor (HHI) Treatment Interruptions and Reinitiations Among Patients with Basal Cell Carcinoma (BCC) in Real-World Clinical Practice. SKIN The Journal of Cutaneous Medicine, 4(6), s123. https://doi.org/10.25251/skin.4.supp.123
Issue
Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Section
Skin Cancer
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

<< < 1 2